Palvella Therapeutics, Inc. (PVLA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$156.85-3.35%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PVLA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -61.2% |
| Our one-year growth estimate | diamond | -38.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 23.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PVLA — earnings miss
Dated 2026-08-04
Results of Operations and Financial Condition. On August 4, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section…
Why it matters: Palvella plans a standalone U.S. launch if the FDA approves the drug. Clear access and patient support plans would show readiness.
Supportive ifBy the FDA decision, Palvella lists steps for specialist outreach, patient support, and market access. If approved, it starts launch in the first half of 2027.
Worry ifPalvella reports that key launch work is delayed, or does not start a launch by the end of the first half of 2027 after approval.
Why it matters: A Phase 3 start would move QTORIN rapamycin into a second late-stage program. A delay would slow that path.
Supportive ifPalvella starts the Phase 3 cutaneous venous malformation trial by the end of 2026.
Worry ifThe trial has not started by the end of 2026, or Palvella reports a pause or delay.
Why it matters: A trial start would add a new program to the pipeline. Palvella planned to begin the study in the second half of 2026.
Supportive ifPalvella starts the Phase 2 DSAP trial by December 31, 2026.
Worry ifPalvella reports no Phase 2 start by December 31, 2026, or says the start is delayed or canceled.
Why it matters: The FDA accepted the NDA and set a priority review date. Approval could make this the first approved treatment for microcystic LMs.
Watch forBy February 28, 2027, the FDA approves QTORIN rapamycin. No new major safety issue appears.
Also watch forThe FDA rejects the NDA, issues a complete response letter, or moves the action date past February 28, 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$200 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $717 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,111 loss on $10,000 · 31.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Palvella is losing money while it funds trials and launch work. Cash fell from $261.9 million in Q1 to $250.6 million in Q2.
Worry ifOn November 10, cash and short-term investments are below $250.6 million. Quarterly net loss is above $21.9 million.
Less concerning ifOn November 10, cash and short-term investments are at least $250.6 million, or quarterly net loss is under $21.9 million.